Interestingly, ovarian and NSCLC cancer patients treated with antimetabolite plus platinum-based chemotherapeutic regimens presented lower ORR in case of SAMHD1 positivity (p = 0.04 and p = 0.016, respectively, Table 4). The gene discussed is SAMHD1; the disease is cancer.